New drug combo targets aggressive brain cancer in early trial
NCT ID NCT07604285
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called MT-125 alongside standard chemoradiation in people newly diagnosed with a specific type of glioblastoma (MGMT methylated). The goal is to find a safe dose and see how well the body handles it. About 36 adults will take part, with the study first finding the right dose, then testing it in more patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Hospital
Phoenix, Arizona, 85054, United States
Contact Email: •••••@•••••
-
Mayo Clinic Hospital
Jacksonville, Florida, 32224, United States
Contact Email: •••••@•••••
-
Mayo Clinic Hospital
Rochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?